The cells of origin of pancreatic gastrinomas remain an enigma, since no gastrin-expressing cells are found in the normal adult pancreas. It was proposed that the cellular origin of pancreatic gastrinomas may come from either the pancreatic cells themselves or gastrin-expressing cells which have migrated from the duodenum. In the current study, we further characterized previously described transient pancreatic gastrin-expressing cells using cell lineage tracing in a pan-pancreatic progenitor and a pancreatic endocrine progenitor model. We provide evidence showing that pancreatic gastrin-expressing cells, found from embryonic day 12.5 until postnatal day 7, are derived from pancreatic Ptf1a ؉ and neurogenin 3-expressing (Ngn3 ؉ ) progenitors. Importantly, the majority of them coexpress glucagon, with 4% coexpressing insulin, indicating that they are a temporary subpopulation of both alpha and beta cells. Interestingly, Men1 disruption in both Ngn3 progenitors and beta and alpha cells resulted in the development of pancreatic gastrin-expressing tumors, suggesting that the latter developed from islet cells. Finally, we detected gastrin expression using three human cohorts with pancreatic endocrine tumors (pNETs) that have not been diagnosed as gastrinomas (in 9/34 pNETs from 6/14 patients with multiple endocrine neoplasia type 1, in 5/35 sporadic nonfunctioning pNETs, and in 2/20 sporadic insulinomas), consistent with observations made in mouse models. Our work provides insight into the histogenesis of pancreatic gastrin-expressing tumors. G astrinomas are endocrine tumors which secrete the peptide hormone gastrin. They cause Zollinger-Ellison syndrome (ZES), characterized by multiple duodenal-jejunal ulcers, diarrhea, and gastroesophageal reflux (1). Most gastrin-producing cells are found in the adult gastric antrum and, to a lesser extent, in the proximal duodenum in mammals. Intriguingly, most primary gastrinomas are found in the duodenum. The rest are mainly in the pancreas and are only rarely found in the stomach and elsewhere (liver, lung, and ovaries) (2). Gastrinomas develop either sporadically or hereditarily, as seen in patients with multiple endocrine neoplasia type 1 (MEN1; disease identifier OMIM131100). MEN1 patients develop multiple tumors in endocrine organs, primarily affecting parathyroid glands, the pituitary, the pancreas, and the foregut. Gastrinomas are the most common functioning tumors of the gastroenteropancreatic axis in MEN1 patients (3, 4), displaying multiple small lesions in the duodenum and, in rare cases, in the pancreas. Sporadic gastrinomas are often solitary tumors occurring both in the duodenum and in the pancreas, and the etiology is poorly understood. Interestingly, somatic MEN1 mutations and a loss of heterozygosity at the MEN1 locus have been detected in approximately 30% of both sporadic duodenal and pancreatic gastrinomas (5, 6). In addition, we have previously reported gastrin-expressing pancreatic tumors in about 15% of heterozygous Men1 mutant mice (7), confirming that M...